India, July 28 -- GSK plc (GSK) announced plans to build a new global R&D centre on the Cambridge Biomedical Campus, reinforcing its commitment to UK life sciences with a £400 million investment over three years.
The 300,000 square-foot site will house more than 1,000 scientists and serve as GSK's UK R&D hub, providing direct access to one of Europe's largest biomedical ecosystems. The centre will feature state-of-the-art labs supporting research in oncology, respiratory, hepatology, vaccines and HIV.
CEO Luke Miels said the move will accelerate GSK's pipeline and integrate the company further into Cambridge's world-class research environment, while Chief Scientific Officer, Tony Wood, described the campus as a catalyst for faster me...